BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Auricchio F, Scavone C, Cimmaruta D, Di Mauro G, Capuano A, Sportiello L, Rafaniello C. Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opin Drug Saf 2017;16:1359-71. [PMID: 28976217 DOI: 10.1080/14740338.2017.1388371] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Chung KK, Altmann D, Barkhof F, Miszkiel K, Brex PA, O'Riordan J, Ebner M, Prados F, Cardoso MJ, Vercauteren T, Ourselin S, Thompson A, Ciccarelli O, Chard DT. A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. Ann Neurol 2020;87:63-74. [PMID: 31693200 DOI: 10.1002/ana.25637] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
2 Paolicelli D, Manni A, Iaffaldano A, Trojano M. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis. CNS Drugs 2020;34:65-92. [PMID: 31898276 DOI: 10.1007/s40263-019-00691-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
3 Ng HS, Rosenbult CL, Tremlett H. Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review. Expert Opin Drug Saf 2020;19:1069-94. [PMID: 32799563 DOI: 10.1080/14740338.2020.1807002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
4 Scavone C, Di Mauro C, Brusco S, Bertini M, di Mauro G, Rafaniello C, Sportiello L, Rossi F, Capuano A. Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy. Expert Opinion on Drug Safety 2019;18:427-33. [DOI: 10.1080/14740338.2019.1598969] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 El-seedi HR, Khalifa SA, El-wahed AA, Gao R, Guo Z, Tahir HE, Zhao C, Du M, Farag MA, Musharraf SG, Abbas G. Honeybee products: An updated review of neurological actions. Trends in Food Science & Technology 2020;101:17-27. [DOI: 10.1016/j.tifs.2020.04.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
6 Mascolo A, Ruggiero R, Sessa M, Scavone C, Sportiello L, Rafaniello C, Rossi F, Capuano A. Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System. Front Pharmacol 2019;10:425. [PMID: 31114497 DOI: 10.3389/fphar.2019.00425] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
7 Maniscalco GT, Scavone C, Moreggia O, Di Giulio Cesare D, Aiezza ML, Guglielmi G, Longo G, Maiolo M, Raiola E, Russo G, Capuano A. Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study. Expert Opin Drug Saf 2022. [PMID: 35189777 DOI: 10.1080/14740338.2022.2044787] [Reference Citation Analysis]
8 Washington F, Langdon D. Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. J Neurol 2021. [PMID: 34676448 DOI: 10.1007/s00415-021-10850-w] [Reference Citation Analysis]
9 Metz LM, Liu W. Effective treatment of progressive MS remains elusive. The Lancet 2018;391:1239-40. [DOI: 10.1016/s0140-6736(18)30426-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
10 Scavone C, Stelitano B, Rafaniello C, Rossi F, Sportiello L, Capuano A. Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System. J Gambl Stud 2020;36:85-96. [PMID: 30671764 DOI: 10.1007/s10899-019-09828-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Scavone C, di Mauro G, Mascolo A, Berrino L, Rossi F, Capuano A. The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs. Front Pharmacol 2019;10:111. [PMID: 30814951 DOI: 10.3389/fphar.2019.00111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
12 D'Amico E, Zanghì A, Romeo M, Cocco E, Maniscalco GT, Brescia Morra V, Paolicelli D, De Luca G, Galgani S, Amato MP, Salemi G, Inglese M, Confalonieri PA, Lus G, Avolio C, Gallo A, Vianello M, Onofrj M, Filippi M, Trojano M, Patti F. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. Neurotherapeutics 2021. [PMID: 33528815 DOI: 10.1007/s13311-020-01001-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
13 D'Amico E, Chisari CG, Arena S, Zanghì A, Toscano S, Lo Fermo S, Maimone D, Castaing M, Sciacca S, Zappia M, Patti F. Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort. Front Neurol 2019;10:337. [PMID: 31024431 DOI: 10.3389/fneur.2019.00337] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
14 Li QW, Lei W, Chen C, Guo W. Recent advances of long noncoding RNAs involved in the development of multiple sclerosis. Chin J Nat Med 2020;18:36-46. [PMID: 31955822 DOI: 10.1016/S1875-5364(20)30003-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Fletcher SP, Choi M, Ogrodnik N, O'Reilly MA. A Porcine Model of Transvertebral Ultrasound and Microbubble-Mediated Blood-Spinal Cord Barrier Opening. Theranostics 2020;10:7758-74. [PMID: 32685018 DOI: 10.7150/thno.46821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Messinis L, Kosmidis MH, Nasios G, Konitsiotis S, Ntoskou A, Bakirtzis C, Grigoriadis N, Patrikelis P, Panagiotopoulos E, Gourzis P, Malefaki S, Papathanasopoulos P. Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial. Mult Scler Relat Disord 2020;39:101932. [PMID: 31927200 DOI: 10.1016/j.msard.2020.101932] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
17 Gajofatto A, Turatti M. Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis. Expert Opinion on Investigational Drugs 2018;27:273-86. [DOI: 10.1080/13543784.2018.1442437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Cree BAC, Goldman MD, Corboy JR, Singer BA, Fox EJ, Arnold DL, Ford C, Weinstock-Guttman B, Bar-Or A, Mientus S, Sienkiewicz D, Zhang Y, Karan R, Tenenbaum N; ASSESS Trial Investigators. Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol 2020. [PMID: 32852530 DOI: 10.1001/jamaneurol.2020.2950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Florou D, Katsara M, Feehan J, Dardiotis E, Apostolopoulos V. Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab. Brain Sci 2020;10:E758. [PMID: 33092190 DOI: 10.3390/brainsci10100758] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
20 Connolly A, Grandi V, Stefanato C, Palmer R, Weir A, Whittaker S. Primary cutaneous CD30 + anaplastic large-cell lymphoma associated with fingolimod. Br J Dermatol 2018;179:1400-1. [DOI: 10.1111/bjd.17003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Robinson-Agramonte MLA, Gonçalves CA, Farina de Almeida R, González Quevedo A, Chow S, Velázquez Pérez L, Díaz de la Fé A, Sesterheim P, Souza DOG. Neuroinflammation and Neuromodulation in Neurological Diseases. Behav Sci (Basel) 2019;9:E99. [PMID: 31547441 DOI: 10.3390/bs9090099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
22 Hočevar K, Ristić S, Peterlin B. Pharmacogenomics of Multiple Sclerosis: A Systematic Review. Front Neurol 2019;10:134. [PMID: 30863357 DOI: 10.3389/fneur.2019.00134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
23 Bittner B, Richter W, Schmidt J. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. BioDrugs 2018;32:425-40. [PMID: 30043229 DOI: 10.1007/s40259-018-0295-0] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 29.3] [Reference Citation Analysis]
24 García-Fernández FJ, García-Fernández AE, Nava E, Del Pozo JSG, Ikuta I, Jordan J, Galindo MF. A bibliometric evaluation of the top 100 cited natalizumab articles. J Neuroimmunol 2020;349:577379. [PMID: 33007648 DOI: 10.1016/j.jneuroim.2020.577379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Uzunköprü C, Beckmann Y. Flammer syndrome in multiple sclerosis: diagnostics, prediction, and personalization of treatments. EPMA J 2019;10:437-44. [PMID: 31832117 DOI: 10.1007/s13167-019-00179-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Sharif NA. iDrugs and iDevices Discovery Research: Preclinical Assays, Techniques, and Animal Model Studies for Ocular Hypotensives and Neuroprotectants. J Ocul Pharmacol Ther 2018;34:7-39. [PMID: 29323613 DOI: 10.1089/jop.2017.0125] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
27 Sharif NA. Glaucomatous optic neuropathy treatment options: the promise of novel therapeutics, techniques and tools to help preserve vision. Neural Regen Res 2018;13:1145-50. [PMID: 30028313 DOI: 10.4103/1673-5374.235017] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
28 Marangi A, Farina G, Vicenzi V, Forlivesi S, Calabria F, Marchioretto F, Forgione A, Rossi F, Stenta G, Vianello M, Gajofatto A, Benedetti MD. Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy. Mult Scler Relat Disord 2020;41:102004. [PMID: 32078935 DOI: 10.1016/j.msard.2020.102004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zanghì A, D'Amico E, Patti F. Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment. Expert Rev Neurother 2020;20:771-82. [PMID: 31971026 DOI: 10.1080/14737175.2020.1721282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Rezaee M, Keshavarz K, Izadi S, Jafari A, Ravangard R. Economic burden of multiple sclerosis: a cross-sectional study in Iran. Health Econ Rev 2022;12:2. [PMID: 34981265 DOI: 10.1186/s13561-021-00350-y] [Reference Citation Analysis]
31 Maniscalco GT, Brescia Morra V, Florio C, Lus G, Tedeschi G, Cianfrani M, Docimo R, Miniello S, Romano F, Sinisi L, Spitaleri DLA, Longo G, Trama U, Triassi M, Fasm Group, Scavone C, Capuano A. Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project. Pharmaceuticals (Basel) 2020;13:E466. [PMID: 33333889 DOI: 10.3390/ph13120466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Chen H, Ma X, Si L, Chen Z, Lin X, Yang Y, Chen X. Traditional Chinese Medicine in Multiple Sclerosis: Theory and Practice. Curr Pharmacol Rep 2018;4:436-46. [DOI: 10.1007/s40495-018-0158-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]